Accumulation of sestamibi in lymphoma cell lines in vitro

Leukemia and Lymphoma

Volumn 38, Issue 5-6, 2000, Pages 599-603

  Kim, Michelle ^c   Gronda, Marcela V ^c   Messner, Hans A ^a   Ballinger, James R ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Human lymphoma; Lymphoma cells; Multidrug resistance; Sestamibi

Indexed keywords

GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NIGERICIN; VALINOMYCIN;

ARTICLE; CELL LINE; CELL MEMBRANE; CONTROLLED STUDY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; HYPERPOLARIZATION; IMAGING; IN VITRO STUDY; LYMPHOMA; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 0033853788     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009059279     Document Type: Article

References (24)

1. Hagemeister, F. B., Fesus, S. M., Lamki, L. M. and Haynie, T. P. (1990) Role of the gallium scan in Hodgkin's disease. Cancer, 65, 1090-1096.
2. Bangerter, M., Griesshammer, M. and Bergmann, L. (1999) Progress in medical imaging of lymphoma and Hodgkin's disease. Current Opinion in Oncology, 11, 339-342.
3. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94, 429-433.
4. Wiedmann, E., Baican, B., Hertel, A., Baum, R. P., Chow, K. U., Knupp, B., Adams, S., Hor, G., Hoelzer, D. and Mitrou, P.S. (1999) Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leukemia and Lymphoma, 34, 545-551.
5. Piwnica-Worms, D. and Holman, B. L. (1990) Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes. Journal of Nuclear Medicine, 31, 1166-1167.
6. Cwikla, J. B., Buscombe, J. R., Kolasinska, A. D., Parbhoo, S. P., Thakrar, D. S. and Hilson, A. J. (1999) Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancer. Anticancer Research, 19, 2299-2304.
7. Ziegels, P., Nocaudie, M., Huglo, D., Deveaux, M., Detourmignies, L., Wattel, E. and Marchandise, X. (1995) Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas. European Journal of Nuclear Medicine, 22, 126-131.
8. Maurea, S., Acampa, W., Varrella, P., De Rosa, V., Fimiani, P., Abate, G. and Salvatore, M. (1998) Tc-99m sestamibi imaging in the diagnostic assessment of patients with lymphomas: comparison with clinical and radiological evaluation. Clinical Nuclear Medicine, 23, 283-290.
9. Dimitrikopoulou-Strauss, A., Strauss, L. G., Goldschmidt, H., Lorenz, W. J., Maier-Borst, W. and van Kaick, G. (1995) Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. European Journal of Nuclear Medicine, 22, 434-442.
10. Kapucu, L. O., Akyuz, C., Vural, G., Oguz, A., Atasever, T., Buyukpamukeu, M. and Unlu M. (1997) Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. Journal of Nuclear Medicine, 38, 243-247.
11. Pinwica-Worms, D., Chiu, M. L., Budding, M., Kronauge, J. F., Kramer, R. A. and Croop, J. M. (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Research, 53, 977-984.
12. m-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nuclear Medicine Communications, 16, 253-257.
13. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. British Journal of Cancer, 77, 353-358.
14. Chang, H., Blondal, J. A., Benchimol, S., Minden, M.D. and Messner, H. A. (1995) p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leukemia and Lymphoma, 19, 165-171.
15. Tweeddale, M. E., Lim, B., Jamal, N., Robinson, J., Zalcberg, J., Lockwood, G., Minden, M. D. and Messner, H. A. (1987) The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood, 69, 1307-1314.
16. Chang, H., Messner, H. A., Wang, X.-H., Yee, C., Addy, L., Meharchand, J. and Minden, M. D. (1992) A human lymphoma cell line with multiple immunoglobulin rearrangements. Journal of Clinical Investigation, 89, 1014-1020.
17. Hyafil, F., Vergely, C., DuVignaud, P. and Grand-Perret, T. (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Research, 53, 4595-4602.
18. Twentyman, P. R. (1988) Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. British Journal of Cancer, 57, 254-258.
19. Chiu, M. L., Kronauge, J. F. and Piwnica-Worms, D. (1990) Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. Journal of Nuclear Medicine, 31, 1646-1653.
20. Bosch, I., Crankshaw, C. L., Piwnica-Worms, D. and Croop, J. M. (1997) Characterization of functional assays of multidrug resistance P-glycoprotein transport activity. Leukemia, 11, 1131-1137.
21. m-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. Nuclear Medicine Communications, 20, 115-122.
22. Nooter, K., Burger, H. and Stoter, G. (1996) Multidrug resistance-associated protein (MRP) in haematological malignancies. Leukemia and Lymphoma, 20, 381-387.
23. Delmon-Moingeon, L. I., Piwnica-Worms, D., Van den Abbeele, A. D., Holman, B. L., Davison, A. and Jones, A. G. (1990) Uptake of the cationic hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Research, 50, 2198-2202.
24. Ballinger, J. R., Li, J.-H., Liu, F.-F. and Boxen, I. (1998) Sestamibi accumulation in nasopharyngeal carcinoma cell lines in vitro. Journal of Nuclear Medicine, 39, 314P.